Manuel Carbonell: Combining Sclerotherapy and Laser Technology in Modern Vein Treatment
Manuel Carbonell, Director at the Center of Phlebology, shared a post on LinkedIn:
“Sclerotherapy remains the first-line treatment for spider veins in most international guidelines and consensus documents. However, every phlebologist has encountered those particularly resistant telangiectasias: fine residual vessels that persist despite technically successful sclerotherapy.
In these cases, an interesting complementary strategy is what could be described as laser after sclerotherapy — the use of transdermal laser as an adjunctive tool for treating residual or refractory spider veins following sclerotherapy.
In my experience, one device that offers several practical advantages for this approach is the Blue Laser by ORLIGHT.
Beyond its portability and ease of use in daily practice, it also represents a relatively affordable option for physicians compared with larger and more complex laser platforms.
According to publicly available manufacturer information, the device has also received FDA clearance for specific dermatologic and vascular indications.
More importantly, the real challenge is not the device itself, but proper patient selection, understanding the underlying venous pathophysiology, and integrating different treatment modalities in a rational and evidence-based way.
Perhaps the future of aesthetic venous treatment will not depend on defending a single technique, but on learning how to combine sclerotherapy, laser technology, and hemodynamic management into increasingly personalized strategies.”

Stay updated with Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia